NewroBus for the brain: humanized TfR1-targeting nanobodies with high BBB permeability and cargo transport capacity
Tao YiniD, Metin YeşiltepeiD, Sanjay Kisan MetkariD, Aubin RamoniD, Matthew GreenigiD, Pietro SormanniiD, Luciano D'adamioiD
Abstract
Effective delivery of therapeutics to the brain is restricted by the blood-brain barrier (BBB). A strategy to overcome this limitation involves taking advantage of receptor-mediated transcytosis pathways, such as those mediated by transferrin receptor 1 (TfR1), which is highly expressed on brain endothelial cells and naturally transports iron-bound transferrin across the BBB. To exploit this mechanism, we immunized camelids with human TfR1 and cloned 470 VHH nanobody sequences from their B cells. From this repertoire, 24 nanobodies (TfR1b-Nbs) were identified that bind human TfR1 on the cell membrane. These nanobodies were screened for binding to human TfR1, lack of interference with transferrin binding and TfR1-mediated iron uptake, and the ability to cross the BBB via human TfR1-mediated transcytosis in newly generated humanized Tfr1h knock-in rats. To improve developability and reduce potential immunogenicity, selected TfR1b-Nbs were humanized and optimized with computational and artificial intelligence (AI) algorithms, enhancing humanness, solubility, and VHH-nativeness. Eight optimized TfR1b-Nbs retained BBB permeability and were fused to humanized anti-TNF nanobody inhibitors (TNFI- or TNFI-{beta}), generating 16 heterodimers. Fusion to these TNFIs served as a functional readout, confirming that TfR1b-Nbs can shuttle biologically active, BBB-impermeable payloads into the central nervous system (CNS). All heterodimers demonstrated CNS delivery after intravenous administration, and selected constructs also reached the brain via subcutaneous injection, maintaining high serum and cerebrospinal fluid (CSF) levels for up to 72 hours. A pilot study with one heterodimer showed that chronic administration in rats humanized for both transferrin and TfR1 caused no hematological toxicity or signs of anemia - a key safety concern when targeting TfR1. These results establish humanized TfR1b-Nbs - designated NewroBus - as promising BBB shuttles for the safe and effective therapeutic delivery of biologics to the brain.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Blood-brain barrier transport using a high-affinity, brain-selective VNAR (Variable Domain of New Antigen Receptor) antibody targeting transferrin receptor 1
Paweł Stocki, Jarosław Szary, … Julia Lynn Rutkowski·bioRxiv·Jul 20, 2020
- Humanized TfR1 and transferrin gene-replacement rats for in vivo evaluation of BBB transport
Metin Yeşiltepe, Sanjay Kisan Metkar, … Luciano D'adamio·bioRxiv·Jul 25, 2025
- Novel VHH targeting a unique TfR1 epitope for efficient cross-species delivery of drugs in the CNS
Marion David, Romy Cohen, … Michel Khrestchatisky·Journal of Controlled ReleasePeer-reviewed·Oct 17, 2025
- NN-800s: Brain-penetrant trimeric nanobodies enable potent TNFα inhibition via TfR1-mediated transcytosis
Tao Yin, Sanjay Kisan Metkar, … Luciano D'adamio·bioRxiv·Apr 30, 2026
- Delivery of small interfering RNA and antisense oligonucleotides across the blood-brain barrier with monovalent transferrin receptor 1 binding VHH-Fc fusion proteins
Ian J. Huggins, Michele Carrer, … Eric E. Swayze·bioRxiv·Aug 20, 2026
- pH-dependent anti-TfR1 NANOBODY(R) molecules deliver efficacious oligonucleotide payloads to muscle and CNS tissues
Emily A Hoyt, Kristof Moonens, … Nina C. Leksa·bioRxiv·Aug 3, 2026